Vaxart, Inc. (VXRT): Shareholders' Equity
$87.80M
As of 2025-12-31
$82.37M
As of 2026-06-30
-7.4%
3-year compound annual growth
-6.6%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $87.80M | +49.0% | 2026-03-13, Balance as of period end |
| 2024-12-31 | $58.92M | +1.9% | 2026-03-13, Balance as of period end |
| 2023-12-31 | $57.80M | -47.7% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $110.60M | -41.0% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $187.53M | +52.0% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $123.40M | +852.8% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $12.95M | +15.3% | 2022-02-24, Balance as of period end |
| 2018-12-31 | $11.24M | n/m | 2021-02-25, Balance as of period end |
| 2017-12-31 | -$38.72M | n/a | 2019-02-06, Balance as of period end |
| 2017-06-30 | $18.70M | -59.5% | 2017-09-01, Balance as of period end |
| 2016-06-30 | $46.20M | -33.5% | 2017-09-01, Balance as of period end |
| 2015-06-30 | $69.50M | -20.0% | 2016-09-13, Balance as of period end |
| 2014-06-30 | $86.90M | +27.8% | 2016-09-13, Balance as of period end |
| 2013-06-30 | $68.00M | +14.7% | 2015-09-11, Balance as of period end |
| 2012-06-30 | $59.30M | n/a | 2014-09-30, Balance as of period end |
| 2011-12-31 | $58.87M | n/a | 2012-03-14, Balance as of period end |
| 2011-06-30 | $81.40M | n/a | 2013-09-27, Balance as of period end |
| 2010-12-25 | $60.57M | -37.8% | 2012-03-14, Balance as of period end |
| 2009-12-26 | $97.41M | n/a | 2012-03-14, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Vaxart, Inc. (VXRT) | 2025-12-31 | $87.80M | +49.0% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $698.58M | -1.7% |
| Vericel Corp (VCEL) | 2025-12-31 | $354.64M | +21.5% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $218.79M | +7.9% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $11.85M | -70.0% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $102.73M | -60.4% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $508.59M | -29.0% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $472.96M | +0.1% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $1.22B | +28.9% |
Compare VXRT, IOVA, VCEL, ADPT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗